OncoPPi-informed discovery of Mitogen-Activated Protein Kinase Kinase 3 as a novel binding partner of c-Myc

Mitogen-activated protein kinase kinase 3 (MKK3) is a dual threonine/tyrosine protein kinase that regulates inflammation, proliferation and apoptosis through specific phosphorylation and activation of the p38 mitogen-activated protein kinase. However, the role of MKK3 beyond p38-signaling remains elusive. Recently, we reported a protein–protein interaction (PPI) network of cancer-associated genes, termed OncoPPi, as a resource for the scientific community to generate new biological models. Analysis of the OncoPPi connectivity identified MKK3 as one of the major hub proteins in the network. Here, we show that MKK3 interacts with a large number of proteins critical for cell growth and metabolism, including the major oncogenic driver MYC. Multiple complementary approaches were used to demonstrate the direct interaction of MKK3 with MYC in vitro and in vivo. Computational modeling and experimental studies mapped the interaction interface to the MYC helix-loop-helix domain and a novel 15-residue MYC-binding motif in MKK3 (MBM). The MBM in MKK3 is distinct from the known binding sites for p38 or upstream kinases. Functionally, MKK3 stabilized MYC protein, enhanced its transcriptional activity and increased expression of MYC-regulated genes. The defined MBM peptide mimicked the MKK3 effect in promoting MYC activity. Together, the exploration of OncoPPi led to a new biological model in which MKK3 operates by two distinct mechanisms in cellular regulation through its phosphorylation of p38 and its activation of MYC through PPI.

[1]  K. Tomczak,et al.  The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge , 2015, Contemporary oncology.

[2]  Anti‐proliferative effects of γ‐tocotrienol are associated with suppression of c‐Myc expression in mammary tumour cells , 2015, Cell proliferation.

[3]  Yutaka Kodama,et al.  Bimolecular fluorescence complementation (BiFC): a 5-year update and future perspectives. , 2012, BioTechniques.

[4]  I. Jurisica,et al.  Identifying Myc interactors. , 2013, Methods in molecular biology.

[5]  H. Li,et al.  USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer , 2014, Oncogene.

[6]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[7]  W. Tansey,et al.  Proteolytic control of the oncoprotein transcription factor Myc. , 2011, Advances in cancer research.

[8]  H. Saito,et al.  Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. , 2005, Molecular cell.

[9]  TylerZARUBIN,et al.  Activation and signaling of the p38 MAP kinase pathway , 2005 .

[10]  Benito Munoz,et al.  Towards patient-based cancer therapeutics , 2010, Nature Biotechnology.

[11]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[12]  Elias Campo Guerri,et al.  International network of cancer genome projects , 2010 .

[13]  G. Liao,et al.  Regulation of c-Myc protein stability by proteasome activator REGγ , 2014, Cell Death and Differentiation.

[14]  C. Sander,et al.  Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations , 2014 .

[15]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[16]  Martin Blackledge,et al.  Structure and dynamics of the MKK7–JNK signaling complex , 2015, Proceedings of the National Academy of Sciences.

[17]  E. Wagner,et al.  Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.

[18]  A. Garufi,et al.  Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications , 2015, Cell Death and Disease.

[19]  Stephen K. Burley,et al.  X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors , 2003, Cell.

[20]  D. Goss,et al.  Thermodynamics of protein-protein interactions of cMyc, Max, and Mad: effect of polyions on protein dimerization. , 2006, Biochemistry.

[21]  A. Cuadrado,et al.  Mechanisms and functions of p38 MAPK signalling. , 2010, The Biochemical journal.

[22]  Lee A. D. Cooper,et al.  The OncoPPi network of cancer-focused protein–protein interactions to inform biological insights and therapeutic strategies , 2017, Nature Communications.

[23]  M. Eilers,et al.  Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.

[24]  E. Prochownik,et al.  Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics. , 2015, Journal of medicinal chemistry.

[25]  S. Lorenz,et al.  Cdc28 kinase activity regulates the basal transcription machinery at a subset of genes , 2012, Proceedings of the National Academy of Sciences.

[26]  Xiao-xin Sun,et al.  The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc , 2015, Proceedings of the National Academy of Sciences.

[27]  S. Oliviero,et al.  PIM1-dependent phosphorylation of Histone H3 at Serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. , 2007 .

[28]  Charles Y. Lin,et al.  Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.

[29]  C. Marshall,et al.  Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2 , 1998, Current Biology.

[30]  Javier León,et al.  Myc and cell cycle control. , 2015, Biochimica et biophysica acta.

[31]  S. Rodig,et al.  Altered Subcellular Localization of c-Myc Protein Identifies Aggressive B-cell Lymphomas Harboring a c-MYC Translocation , 2010, The American journal of surgical pathology.

[32]  John S Lazo,et al.  Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.

[33]  I. Jurisica,et al.  Myc and its interactors take shape. , 2015, Biochimica et biophysica acta.

[34]  Jeffrey E. Lee,et al.  Measuring Protein‐Protein and Protein‐Nucleic Acid Interactions by Biolayer Interferometry , 2015, Current protocols in protein science.

[35]  R. Davis,et al.  Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-58 and Ser-62. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Knapp,et al.  Structural and Functional Characterization of the Human Protein Kinase ASK1 , 2007, Structure.